Publications by authors named "Jorg Basecke"

Claim this Profile
D
Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer.
Rike Geiken-Weinstock, Frank Griesinger, Michael Metz, Ralf Georg Meyer, Peter Staib

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early versus Delayed Tumor-Specific Therapy and Survival in Patients with Lung Cancer: A Retrospective Study.
Rike Geiken-Weinstock, Anna K L Reyners, Frank Griesinger, Burkhard Joerg Otremba, Michael Hoheisel

Oncol Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer therapy and treatments during COVID-19 era.
Shaw M Akula, Stephen L Abrams, Linda S Steelman, Saverio Candido, Massimo Libra, Jorg Basecke

Adv Biol Regul· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[42-year-old patient with renal insufficience, anemia and thrombocytopenia during chemotherapy].
Gerhard Schoel, Joachim Schrader, Jörg Bäsecke

Dtsch Med Wochenschr· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[ELITE study - Nutrition, lifestyle and individual information for the prevention of stroke, dementia and heart attack - Study design and cardiovascular status].
Stephan Lüders, Bastian Schrader, Jörg Bäsecke, Hermann Haller, Albrecht Elsässer

Dtsch Med Wochenschr· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[31-year-old Male with Epigastric Pain].
Wolfgang Heywinkel, Lars Daniel Berthold, Jörg Bäsecke

Dtsch Med Wochenschr· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[67-year old woman with long-standing microcytic anemia].
Friederike Braulke, Stephan Lüders, Jörg Bäsecke

Dtsch Med Wochenschr· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary osteomyelofibrosis and an XX-male genotype.
Julie Schanz, Detlef Haase, Peter Steuernagel, Katayoo Shirneshan, Jörg Bäsecke

Eur J Haematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK-3 as potential target for therapeutic intervention in cancer.
James A McCubrey, Linda S Steelman, Fred E Bertrand, Nicole M Davis, Melissa Sokolosky, Jorg Basecke

Oncotarget· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.
James A McCubrey, Nicole M Davis, Stephen L Abrams, Giuseppe Montalto, Melchiorre Cervello, Jorg Basecke

Adv Biol Regul· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in targeting signal transduction pathways.
James A McCubrey, Linda S Steelman, William H Chappell, Lin Sun, Nicole M Davis

Oncotarget· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.
James A McCubrey, Linda S Steelman, William H Chappell, Stephen L Abrams, Richard A Franklin

Oncotarget· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycobiology in malignant gliomas: expression and functions of galectins and possible therapeutic options.
Herwig M Strik, Malgorzata Kolodziej, Wolfgang Oertel, Jorg Basecke

Curr Pharm Biotechnol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
James A McCubrey, Linda S Steelman, William H Chappell, Stephen L Abrams, Giuseppe Montalto

Oncotarget· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the cancer initiating cell: the ultimate target for cancer therapy.
James A McCubrey, Linda S Steelman, Stephen L Abrams, Negin Misaghian, William H Chappell, Jorg Basecke

Curr Pharm Des· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
James A McCubrey, Linda S Steelman, C Ruth Kempf, William H Chappell, Stephen L Abrams

J Cell Physiol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
William H Chappell, Linda S Steelman, Jacquelyn M Long, Ruth C Kempf, Stephen L Abrams

Oncotarget· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.
Linda S Steelman, William H Chappell, Stephen L Abrams, Ruth C Kempf, Jacquelyn Long

Aging (Albany NY)· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.
Stephen L Abrams, Linda S Steelman, John G Shelton, William Chappell, Jörg Bäsecke

Cell Cycle· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
Stephen L Abrams, Linda S Steelman, John G Shelton, Ellis W T Wong, William H Chappell

Cell Cycle· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
Linda S Steelman, Stephen L Abrams, John G Shelton, William H Chappell, Jörg Bäsecke

Cell Cycle· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation.
William L Blalock, Cecilia Grimaldi, Federica Fala, Matilde Follo, Stefan Horn, Jorg Basecke

J Cell Physiol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.
James A McCubrey, Melissa L Sokolosky, Brian D Lehmann, Jackson R Taylor, Patrick M Navolanic

Adv Enzyme Regul· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Akt as a therapeutic target in cancer.
Linda S Steelman, Kristin M Stadelman, William H Chappell, Stefan Horn, Jörg Bäsecke

Expert Opin Ther Targets· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity.
James A McCubrey, Jörg Bäsecke, Melchiorre Cervello, Alberto M Martelli, Richard A Franklin

Cancer Biol Ther· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis